Clinical Trial

Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of the study is to evaluate the effect of setrusumab on reduction in fracture rate, including morphometric vertebral fractures.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2024-10-08; most recent amendment 2026-06-11.
Status change: Recruiting → Active, Not Recruiting 2025-01-31
Status change: Not Yet Recruiting → Recruiting 2024-11-14
Trial Details
NCT Number NCT06636071
Lead Sponsor Ultragenyx Pharmaceutical Inc
Conditions Osteogenesis Imperfecta
Enrollment 6 participants
Start Date 2024-10-25
Primary Completion 2027-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-15